Healthcare Stocks

Ramsay (ASX:RHC) ends takeover talks with KKR consortium

 Ramsay (ASX:RHC) ends takeover talks with KKR consortium

Shares of Ramsay dropped on Monday morning after the company shared that it has ended takeover discussions.

Read More...
Pro Medicus (ASX:PME) inks two contract renewals worth AU$47M

Pro Medicus (ASX:PME) inks two contract renewals worth AU$47M

Highlights Pro Medicus has signed a renewal contract with Sutter Health for another seven years. A renewal contract is also inked with Wellspan Health for further five years. The share price of Pro Medicus has gained by over 650% in last 5 yea...

Read More...
Healthcare value stocks from ASX All Ordinaries: HLS, MVF, SHL, ANN

Healthcare value stocks from ASX All Ordinaries: HLS, MVF, SHL, ANN

Highlights Value stocks trade at a lower price corresponding to their fundamentals A high dividend yield and low P/B P/E ratios are common features of value stocks Healius reported a 100% increment in underlying unaudited EBITDA YTD to May 202...

Read More...
Pro Medicus signs US$28M contract with Allina Health; how are shares faring?

Pro Medicus signs US$28M contract with Allina Health; how are shares faring?

  • June 02, 2022 10:54 AM AEST | Ashish

Highlights Pro Medicus signed a 7-year contract with a Minneapolis-based firm Allina Health. The deal with Alline Health is worth AU$28 million. The deal is expected to provide a unified diagnostic imaging platform across the network...

Read More...
AVR, AMT, OSL: ASX medical device stocks with best YTD returns

AVR, AMT, OSL: ASX medical device stocks with best YTD returns

Highlights Medical devices consist of a range of tools and equipment that help enhance healthcare services and save lives Australia exports nearly all medical technology products manufactured in the country Imports fulfil 80% demand for medica...

Read More...
Recent updates from ASX healthcare stocks DXB and GLH

Recent updates from ASX healthcare stocks DXB and GLH

Highlights Dimerix recruits the first subject for its DMX-200 phase 3 trial in patients with FSGS kidney disease. FSGS has a huge market opportunity as in the US alone, end stage renal failure amounted to an estimated cost of US$55 billion per ...

Read More...
Mesoblast (ASX:MSB) posts US$23.1M third-quarter loss; how are shares faring?

Mesoblast (ASX:MSB) posts US$23.1M third-quarter loss; how are shares faring?

  • June 01, 2022 11:14 AM AEST | Ashish

Highlights Mesoblast’s loss after tax for the third quarter FY2022 was US$21.3 million. Total revenue rose 5% from the comparative quarter last year to US$2 million. Despite the loss, Mesoblast’s share price was trading a...

Read More...
CSL, RHC, SHL: 3 ASX health care stocks on investors’ watchlist  

CSL, RHC, SHL: 3 ASX health care stocks on investors’ watchlist  

Highlights CSL has the largest market capitalisation (AU$131.32 billion) in the ASX health care space as of 31 May 2022 In 2020/21, CSL invested US$1,001 million in R&D activities Sonic reported revenue growth of 7% and net profit growth o...

Read More...
A look at 2 ASX-listed dental care stocks: SDI, PSQ

A look at 2 ASX-listed dental care stocks: SDI, PSQ

Highlights Private dental clinics cater to more than 85% of dental care in Australia. Dental care stock SDI, which registered record 1H sales, expects new product releases and continued increases in market share to underpin growth momentum. CO...

Read More...
OPT, BIT, IMM: Updates from ASX biotech players with over 10% returns

OPT, BIT, IMM: Updates from ASX biotech players with over 10% returns

Medical biotechnology leverages living cells and materials to develop diagnostic and pharmaceutical products. The sector has gained traction in recent times as the COVID-19 pandemic has emphasised the importance of a strong drug development system....

Read More...
RAC, CTE, ADO: ASX health stocks with massive returns in past 3 years

RAC, CTE, ADO: ASX health stocks with massive returns in past 3 years

Multibaggers are lucrative stocks that provide returns several times higher than their initial investment value. To be more specific, if a stock price rises by double, it's called a double bagger, while if the price grows multiple times, it's calle...

Read More...

Frequently Asked Questions

Given the fact that healthcare is a necessity, investing in healthcare stocks can be rewarding. However, to make good returns from these stocks, an investor should have sound knowledge about the sector and should be aware of the latest trends in the sector.

The standard checklist that one would run to find a good stock, holds true for screening healthcare stocks too. However, there are few aspects that are important to be considered for healthcare stocks. Well established pharmaceutical stocks with a good history of drug discovery and effective treatments typically have some sort of moat around them, thanks to their scale and financial wherewithal. However, new, and small companies with unique innovations or a strong product pipeline are also worth investigating, as they have a longer runway. Healthcare companies are able to pass on inflation-led input cost pressure, since people usually do not cut back on their healthcare expenses even during an inflationary environment. Companies that are able to maintain good profit margin are seen commanding valuation premiums in the market. Investors can also look for healthcare companies with strong patent portfolio, as patents can provide good price and competition protection for longer periods. Finally, before finalising any share, some of the fundamentals such as return on equity, revenue growth, net margin growth, management capabilities in terms of capital allocation, dividend pay-out should be considered.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK